Regulation of the human Na+-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1

Martín G. Martín1, Jiafang Wang1, R. Sergio Solorzano-Vargas1,3, Jason T. Lam2, Eric Turk2, and Ernest M. Wright2

Departments of 2 Physiology and Pediatrics, 1 Division of Gastroenterology and Nutrition, UCLA School of Medicine, Los Angeles 90095-1751; and 3 Department of Biology, California State University Northridge, Northridge, California 91330


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Na+-glucose cotransporter (SGLT1) is expressed primarily by small intestinal epithelial cells and transports the monosaccharides glucose and galactose across the apical membrane. Here we describe the isolation and characterization of 5.3 kb of the 5'-flanking region of the SGLT1 gene by transiently transfecting reporter constructs into a variety of epithelial cell lines. A fragment (nt -235 to +22) of the promoter showed strong activity in the intestinal cell line Caco-2 but was inactive in a nonintestinal epithelial cell line (Chinese hamster ovary). Within this region, three cis-elements, a hepatocyte nuclear factor-1 (HNF-1) and two GC box sites are critical for maintaining the gene's basal level of expression. The two GC boxes bind to several members of the Sp1 family of transcription factors and, in the presence of HNF-1, synergistically upregulate transactivation of the promoter. A novel 16-bp element just downstream of one GC box was also shown to influence the interaction of Sp1 to its binding site. In summary, we report the identification and characterization of the human SGLT1 minimal promoter and the critical role that HNF-1 and Sp1-multigene members have in enhancing the basal level of its transcription in Caco-2 cells.

intestine; transcription; glucose-galactose malabsorption; Sp2; Sp3


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

THE SODIUM-GLUCOSE TRANSPORTER SGLT1, an integral membrane protein, is located in the apical membrane of the small intestinal enterocyte and transports glucose and galactose against their concentration gradients (46). The human SGLT1 gene is located on the long arm of chromosome 22 (22q13.1), spans 70 kb in length, and consists of 15 exons (41, 42).

SGLT1 is the prototype of the Na+-dependent cotransport family of proteins. Mutations in the coding sequence of its gene are responsible for the autosomal recessive disorder glucose-galactose malabsorption [On line Mendelian Inheritance in Man (OMIM) #182380] (14, 20, 21, 43). Expression of SGLT1 in humans is largely limited to small intestinal enterocytes (12). SGLT1 expression in vivo has been shown to be regulated by various dietary, hormonal, and hard-wired stimuli (7). Intestinal glucose transport capacity in the sheep is particularly dependent on dietary glucose, where SGLT1 protein levels are regulated primarily at a posttranscriptional level (16). In rats, glucose transport was shown to be influenced by a diurnal trigger rather than by changes in dietary glucose (7, 33). In support of this, nuclear run-on assays, performed with nuclei isolated from intestinal epithelial cells, revealed a diurnal pattern of rat SGLT1 transcription that fluctuates by as much as sevenfold (33).

The regulation of the SGLT1 gene provides a model system for evaluation of the mechanism of intestine-specific expression. Compared with our understanding of hepatocyte- and lymphocyte-specific regulation of expression, relatively little is known about trans-acting DNA-binding proteins that affect enterocyte-specific gene expression (6, 40). We do know that expression of the sucrase-isomaltase gene is controlled by cdx-2 and hepatic nuclear factor (HNF)-1alpha /beta homo- and heterodimers, and the lactase gene by the homeodomain protein HOXC11 and the GATA family of nuclear proteins (26, 40). However, transgenic mice expressing these critical cis-elements failed to show correct tissue- and age-specific expression (19). Therefore, despite progress, the transcription factors that can direct expression in epithelial cells of the small intestine have not been identified (36).

To gain better insight into the tissue-specific, developmental, and diet-induced regulation of human SGLT1, we have evaluated the constitutive regulation of the gene, determined a minimal promoter, and identified its critical elements using in vitro assays, including reporter analysis of deletion- and substitution-mutant clones, band-shift, DNase I footprint, and overexpression assays.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of the 5'-flanking region of SGLT1. Cosmid clone H33 contains 25 kb of the 5'-untranslated region (UTR) of SGLT1 (42). H33 was digested with restriction endonucleases, and a Southern blot was probed with an oligonucleotide corresponding to the region immediately upstream of the promoter [(-10/+10) 5'-CTGGCGAGAGGGAAGGACGC-3']. A 5.3-kb Nco I fragment (-5370/+22) corresponding to the SGLT1 5'-UTR contiguous to the initiator methionine codon was subcloned into the luciferase reporter vector pGL3 Basic (Promega) and is referred to as hSGLT1-5370/+22/B-Luc.

SGLT1 nested deletion clones. Nested deletions of the SGLT1 5'-UTR were made by exonuclease and mung bean nuclease digestion (22). Clones were isolated, and their sizes were determined by restriction digestion and sequencing. Constructs hSGLT1-5295/+22/B-Luc, hSGLT1-3852/+22/B-Luc, hSGLT1-3085/+22/B-Luc, hSGLT1-1438/+22/B-Luc, hSGLT1-1041/+22/B-Luc, hSGLT1-641/+22/B-Luc, and hSGLT1-243/+22/B-Luc were chosen for transient transfection analysis. The transcription factor databases of MacVector 5.0 (TFDSITES.SUBSEQ.7.0.aa), and MatInspector 2.1 (http://www.gsf.de/cgi-bin/matsearch.pl) were searched for putative DNA cis-elements (32).

Chimeric SGLT1 promoter-luciferase constructs were created by cloning PCR-derived fragments of the 5'-flanking region into the vector pGL3 Enhancer. PCR was performed with 11 different sense oligonucleotides and an antisense oligonucleotide corresponding to nucleotides +56/+76 from exon 1 (5'-GTGGAGATATCGGCTGCATTGCG). A Hind III restriction site (shown in lowercase) was added to the 5'-portion of each sense primer and includes -27/-9 (5'-gcaagcttTATAAGGAGCTAGCGGCCCT), -37/-18 (5'-gcaagcttCAGGAGGCCGTATAAGGAGC), -50/-29 (5'-gcaagcttTGCTGATCATTAACCAGGAGGC), -83/-62 (5'-gcaagcttTGCTCCCTCAAAGTCCCAGGTC), -136/-114 (5'-gcaagcttTGCTTCCTGACGGTGCAGCCGC), -169/-147 (5'-gcaagcttCGGGTGCTCCTTCCTGGGCTCCA), -235/-213 (5'gcaagcttTGGCCCCTCCCCATTCGCAGGA), -280/-263 (5'-gcaagcttCTGTGGGAGTACAGTGGG-3'), -330/-314 (5'-gca- agcttAGCCACTCCAGCTCTGG-3'), -397/-376 (5'-gcaagcttATGGGTGGCAGGTGATCTGA-3'), and -500/-481 (5'-gcaagcttTCTCCAGGGAGAACAAGAC-3'). PCR fragments were digested with Hind III and Nco I, gel purified, and subcloned into a similarly digested pGL3-Enhancer vector. Clones hSGLT1-500/+22/E-Luc, hSGLT1 -397/+22/E-Luc, hSGLT1-330/+22/E-Luc, hSGLT1-280/+22/E-Luc, hSGLT1-235/+22/E-Luc, hSGLT1-169/+22/E-Luc, hSGLT1-136/+22/E-Luc, hSGLT1-83/+22/E-Luc, hSGLT1-50/+22/E-Luc, hSGLT1-37/+22/ E-Luc, and hSGLT1-27/+22/E-Luc were all confirmed by restriction enzyme and DNA-sequencing analysis.

Scanning mutagenesis. Scanning mutagenesis was done to define the essential constitutive regions of the minimal promoter of SGLT1. Mutagenizing primers (50-mers), containing a central core of 10 mutated nucleotides (Aright-arrowC, Cright-arrowA, Gright-arrowT, Tright-arrowG) and flanked on either side by a span of 20 correct nucleotides, were designed (Fig. 1A). These mutant oligonucleotides were used with an antisense oligonucleotide from exon 1 (nucleotides +56/+76) to perform the initial PCR amplification. The purified fragments M3 through M23 served as a "megaprimer," which together with the -235/-212-Hind III primer were used to amplify the full-length product. These products were then digested with Hind III and Nco I, gel purified, subcloned into the pGL3-Enhancer vector, and sequenced to confirm the mutations.


View larger version (100K):
[in this window]
[in a new window]
 
Fig. 1.   A: oligonucleotides used for developing M1-M23 mutant minimal promoter clones. Location of mutation is signified by boldface lowercase letters, and its location relative to start of transcription is shown at right. B: 5'-upstream sequence of human, rat, and sheep SGLT1 gene. Sequence of -243 nucleotides of 5'-flanking region of human (top) is displayed for direct comparison with sequence of rat isoform (middle) and sheep (bottom) isoform (15, 26, 42). Arrow demonstrates location of experimentally identified site of initiation (+1), and putative TATA box is outlined. Gray shaded regions identify nucleotides that are conserved in all isoforms. Locations of scanning mutagenesis clones are labeled M1 to M23, and their boundaries are defined by small vertical lines. Locations of hepatic nuclear factor (HNF)-1, GC box 1, and GC box 2 are shown for comparison.

The activity of three identified elements was assessed in the presence of the heterologous SV40 promoter. Vectors were developed by subcloning one of four sets of annealed oligonucleotides containing Bgl II and BamH I sites on either end into the Bgl II site of pGL3 Promoter. The oligonucleotides used were GC box 2/HNF sense 5'-GAAGATCTCCCCTCCCCTGGTGCTGATCATTAACC, alpha -sense 5'-CTGGATCCGGTTAATGATCAGCACCAGGGGAGGGG; GC box 2/unrelated sense 5'-GAAGATCTCCCCTCCCCTGGGTAGTCGACGGCCAA, alpha -sense 5'-CTGGATCCTTGGCCGTCGACTACCCAGGGGAGGGG; unrelated/HNF sense 5'-GAAGATCTAAAAGAAAATGGTGCTGATCATTAACC, alpha -sense 5'-CTGGATCCGGTTAATGATCAGCACCATTTTCTTTT; and GC box 1 sense 5'-GAAGATCTGGCCCCTCCCCATTCGCAGGACAGCTCT, alpha -sense 5'-CTGGATCCAGAGCTGTCCTGCGAATGGGGAGGGGCC.

Cell cultures, transfection and nuclear protein isolation. The cell lines Caco-2 (human intestine), LLC-PK1 (porcine kidney) and CHO (Chinese hamster ovary) were obtained from ATCC, and passages 20 to 50 were used for all transfection experiments (17). Transient transfection experiments and luciferase and beta -galactosidase assays were performed (17). The HNF-1alpha and HNF-1beta expression vectors (kindly provided by G. Crabtree, Stanford University), were cotransfected with the specified hSGLT1-Luc and beta -galactosidase vectors. Nuclear extracts were prepared from Caco-2 cells ~5 days after seeding (17).

DNase I footprinting. In vitro DNase I footprint analysis was performed with the hSGLT1-330/+22/E-Luc and hSGLT1-235/+22/E-Luc clones digested with Hind III, radiolabeled with [gamma -32P]dATP (6,000 Ci/mmol), and then cut with Nco I (5' to 3') (17).

Band-shift assays. Band-shift analysis was done as previously described, with the exception of the GC boxes that were analyzed in the presence of 1 mM ZnCl2 (17). Standard competition studies were run using excess cold oligonucleotides. The primers used included wild-type (WT) 19-21 primer, spanning from -51 to -30, sense (5'-GATCTGCTGATCATTAACCAGGAGGC) and alpha -sense (5'-CTAGGCCTCCTGGTTAATGATCAGCA). The mutant (Mut) 19-21 primers used were sense (5'GATCTGCTGATCATgccaCAGGAGGC) and alpha -sense (5'-CTAGGCCTCCTgtggcATGATCAGCA), which contained a mutation in the HNF-1 site (shown in lowercase). Double-stranded oligonucleotides of the consensus Sp1 site (5'-ATTCGATCGGGGCGGGGCGAG) and the CTC site (5'-TTCCCCTCCCCCGGATACTTCACTAGA-3') identified in the trefoil gene were also used in competition experiments. Supershift analysis was performed with antisera provided by G. Crabtree (HNF-1alpha and HNF-1beta , 1 µl each) and Santa Cruz Biotechnology (2 µl of either Sp1, Sp2, or Sp3). Recombinant Sp1 (Promega) was used at a concentration of 0.5 footprint units (FPU) per gel-shift reaction.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The promoter region of human SGLT1 gene. The 5'-untranslated sequence of the human SGLT1 isoform is shown in Fig. 1B and is aligned for direct comparison with the rat (GenBank accession no. 9AF007832) and sheep (GenBank accession no. AJ223077) isoforms (33, 42, 45). Analysis of the 1.5-kb region immediately upstream of the initiator codon for putative cis-acting elements revealed putative binding sites for a single HNF (HNF-1) (-51/-37), three HNF-3beta sites (-187/-175, -707/-696, -1253/-1265), five CCAAT/enhancer binding protein (C/EBP)beta sites (-325/-312, -684/-670, -1035/-1022, -1300/-1287, -1464/-1448), and a single signal transducer and activator of transcription (-346/-338) and cAMP-responsive element binding protein site (-132/-121) (32).

A cloned 5.3-kb genomic Nco I fragment of the promoter region contiguous with the initiator codon was sequenced and found to overlap with a 42-kb cosmid sequence deposited into GenBank (accession no. Z74021). The latter extends more than 26 kb upstream of the transcription start site. Several nucleotide polymorphisms were identified between the two sequences (not shown; GenBank accession no. pending).

Transiently transfected Caco-2, LLC-PK1, and CHO cells. Reporter constructs containing shortened lengths of the promoter region were cloned into the luciferase reporter construct pGL3 Basic and were transfected into Caco-2, LLC-PK1, and CHO cells. In Caco-2 cells, the longer clones had promoter activities ~10-fold higher than the promoterless vector, pGL3 Basic (Fig. 2A). Transfection of the shortest clone (hSGLT1-243/+22/B-Luc) into Caco-2 cells resulted in a 16-fold higher level of promoter activity compared with pGL3 Basic. In contrast, promoter activity was generally lower (eightfold above the empty vector) when tested in LLC-PK1 cells (Fig. 2A). Finally, CHO cells could not support the activity of any size promoter construct. We interpreted these results to suggest that Caco-2 and LLC-PK1 cells are capable of supporting the basal promoter activity of a limited region of the human SGLT1 promoter. These data are consistent with reports that SGLT1 is expressed in Caco-2 and LLC-PK1 cells (18, 29).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Transiently transfected Caco-2 and LLC-PK1 cells support promoter activity of various nested deletion clones. A: relative size of the upstream region of each clone is shown. Calcium phosphate methods were used to cotransfect 1 pmol of vectors of various sizes and 0.1 pmol of cytomegalovirus (CMV)-beta -galactosidase vector. Transfection efficiency and basal luciferase expression were controlled for by transfection of pGL3 Control (containing SV40 enhancer and promoter) and pGL3 Basic. Samples were processed 2 days later, and relative light units (RLU)/ beta -galactosidase activity are displayed as multiples of elevation over promoterless pGL3-Basic vector. Values are means ± SD of triplicate data from 2-4 experiments. CHO, Chinese hamster ovary. B: deletion fragments subcloned into the pGL3-Enhancer vector (1 pmol). Values are means ± SD of triplicate data from 2-4 experiments.

To define the lower size limits of the minimal promoter, 11 chimeric SGLT1 promoter-luciferase constructs were transiently transfected into Caco-2 cells. Fragments ranging from the longest (hSGLT1-500/+22) to a shorter clone (hSGLT1-235/+22) resulted in similar promoter activity, approximately sixfold higher than the promoterless control vector (Fig. 2B). In contrast, promoter activity of shorter clones was indistinguishable from that of the control. Deletion analyses of various lengths (-5295/+22 to -27/+22) of the SGLT1 promoter suggest that its expression was supported best in the human intestinal cell line Caco-2 and that nucleotides -235/+22 represent the gene's minimal promoter (Fig. 2).

DNase I footprint analysis identifies two DNA-protein complexes. Using 5' to 3'-labeled hSGLT1-330/+22 as a template revealed a single DNA-protein complex in the region corresponding to -229 through -206 (named FP-I; Fig. 3). Similarly, a DNase I digest of the hSGLT1-235/+22 vector labeled in the same orientation revealed a second complex located at -49 to -31 in the upstream region of the gene (named FP-II; Fig. 3). No other footprints were identified within bases -270 to +30.


View larger version (83K):
[in this window]
[in a new window]
 
Fig. 3.   DNase I footprint of immediate upstream region of SGLT1 gene. DNase I footprinting analysis was performed on initial 300 bp of immediate SGLT1 region using nuclear extracts from unstimulated Caco-2 cells. DNA fragment labeled in sense orientation was incubated without (-; lanes 1-2 and 5-6) or with (+; lanes 3-4 and 7-8) nuclear protein or nuclear extracts and subjected to DNase I. DNase I enzyme concentration is depicted by triangle. Samples were electrophoresed with a Maxam and Gilbert reaction as described in EXPERIMENTAL PROCEDURES. Shaded boxes labeled FP-I and FP-II indicate only sequences protected within the gene's minimal promoter. Position (nucleotides) of footprint is displayed to left of each box.

Scanning mutagenesis indicates several binding sites for transcriptional activators. Figure 1 shows the location of the mutations in 23 clones named M1 to M23. Each contained a different stretch of 10 mutated contiguous nucleotides within the 260-bp minimal promoter. Transient transfection in Caco-2 cells revealed that the promoter activity of all but two clones (M22 and M17) was significantly lower than the WT hSGLT1-235/+22/E-Luc clone (Fig. 4), suggesting either the existence of numerous cis-acting elements or a pronounced interdependence of regional secondary structure for optimal promoter function. Clones M2, M18, and M20 displayed the most pronounced declines in promoter activity (<20% of WT), suggesting that three exceptionally active cis-elements are located in the gene's minimal promoter region. Indeed, footprints I and II, identified in Fig. 3, correspond to the regions mutated in the M2 (-225/-216) and M20 (-45/-36) clones, respectively.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Transient transfection of clones containing scanning mutations within minimal promoter of SGLT1. Series of clones containing 10-bp mutations (defined in Fig. 1B) within minimal promoter were cotransfected with CMV-beta -galactosidase vector in Caco-2 cells. Relative location of each mutation is represented by a black box on left. Cells were processed 2 days later, and beta -galactosidase and RLU were measured. Data is displayed as multiples of increases over wild-type (WT) hSGLT1-235/+22/E-Luc clone. Values are means ± SD of triplicate data from 3 experiments. * P < 0.01 vs. WT hSGLT1-235/+22/E-Luc clone.

HNF-1 is a potent activator of the SGLT1 minimal promoter. The nucleotide sequence from -51 to -30 accords with a transcription factor HNF-1 consensus (5'-GGTTAATnATTAACCa/c-3'). This domain, corresponding to the M20 clone and footprint II, was further evaluated by band-shift analysis. The WT 19-21 primer (nucleotides -51 to -30) was radiolabeled and found to compete with the Mut 19-21 primer, which contains a critical 4-bp mutation in the HNF-1 site. Figure 5 is a representative band-shift study using the HNF-1 probe that reveals a DNA/protein complex that runs as a smear. This complex was specific because it was competed with a 10-fold excess of the unlabeled HNF-1 oligonucleotide (Fig. 5) but not with either the Mut 19-21 or an unrelated oligonucleotide. Supershift experiments showed a shift of a portion of the specific complex with antiserum to the HNF-1alpha isoform (Fig. 5) and its complete removal by antiserum to the HNF-1beta isoform (Fig. 5).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 5.   Band-shift assays of HNF-1 element identified a specific complex. HNF-1 primer spans from -51 to -30 (WT 19-21). Annealed WT 19-21 primers were labeled with 32P and used for all experiments. Competition experiments were performed with 10-, 50-, 100-, 1,000-fold (lanes 2-5, respectively) excess of cold WT 19-21 primers. In addition, 1,000-fold excess of oligo containing a mutation in HNF-1 site (Mut 19-21) (lane 6) and unrelated (UR) (lane 7) primers were also used. Single DNA-protein complex is indicated with filled arrowheads. Supershift studies were also performed by preincubating nuclear extract with 1 µl of either HNF-1alpha (lane 9) or HNF-1beta antisera (lane 10), and supershifted band is indicated with an open arrowhead.

Either the minimal promoter construct (hSGLT1-235/+22/ E-Luc) or the corresponding promoter construct containing a 10-bp mutation (M20) in the putative HNF-1 site was used to transiently transfect Caco-2 cells, which were cotransfected with vectors expressing the murine versions of either HNF-1alpha or beta . Cotransfecting with the HNF-1alpha expression vector and the minimal promoter construct resulted in a nearly threefold enhancement of promoter activity over WT alone (Fig. 6). Similarly, a modest twofold increase in promoter activity was obtained using the HNF-1beta expression vector. The action of the HNF-1 expression vector on promoter activity was specific to the site identified at -45/-36 because cotransfection with the M20 mutant substituting for the minimal promoter construct abolished inducible transcriptional activity.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   Transient cotransfection of clones containing either SGLT1 minimal promoter (SGLT1) or a mutation in HNF-1 region (M20 SGLT1) and an expression vector expressing either HNF-1alpha or -beta . Cotransfection of 1 pmol of either HNF-1alpha or -beta mammalian expression vector with either hSGLT1-235/+22/E-Luc or hSGLT1-235/+22M20/E-Luc clone was performed using standard CaPO4 method. Cells were processed 2 days later, and beta -galactosidase and RLU were measured. Data are displayed as multiples of increases over promoterless pGL3-Enhancer clone. Values are means ± SD of triplicate data from 2 experiments.

Two regions form specific DNA-protein complexes. A double-stranded oligonucleotide named WT 1-3 was made that encoded domains M1, M2, and M3 (see Fig. 1B; bases -235 to -206). A double-stranded oligonucleotide named WT 17-18 was developed that encodes for domains M17 and M18 (see Fig. 1B; bases -75 to -56). The WT 1-3 probe revealed two prominent DNA-protein complexes (arrowheads) that could be competed entirely with the addition of 90-fold excess of cold WT 1-3 oligo (Fig. 7). Two DNA-protein complexes were also seen with the WT 17-18 probe, but this complex could not be competed with as much as 250-fold excess of cold WT 17-18 duplex (Fig. 7).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 7.   Band-shift assay with WT 1-3 and WT 17-18 primers. Oligonucleotide WT 1-3, which spans from M1 to M3, was labeled with 32P and used for band-shift assays in lanes 1-8. Nuclear extracts (7 µg) from Caco-2 cells were used for each reaction. Competition reactions were performed with various multiples of excesses of WT 1-3 cold primer (lanes 2-8). Primers that span the WT 17-18 area formed 2 complexes that could be competed off with various multiples of excess of cold WT 17-18 primers (lanes 10-14). Arrowheads indicate location of 2 complexes.

GC boxes 1 and 2 bind recombinant Sp1. Because the WT 1-3 and WT 17-18 duplexes share DNA-protein complexes of similar size and sequence (g/tCCCCTCCCC), we hypothesized that the complexes may be attributed to binding of the transcription factor Sp1 to the GC box. To compare the ability of the WT 1-3 (GC box 1) and WT 17-18 (GC box 2) duplexes to bind recombinant Sp1, the WT 1-3 primer was labeled and competition studies were performed with various multiples of excesses of either itself (Fig. 8) or the WT 17-18 duplexes (Fig. 8). Recombinant Sp1 and the WT 1-3 primer form a prominent complex that corresponds in size to that of the slower migrating complex seen with crude nuclear extracts (Fig. 8). Overexposed autoradiograms revealed an additional complex whose molecular weight was approximately twice that of the main complex and may represent Sp1 dimers (Fig. 8). Competition with a 90-fold excess of either the consensus Sp1 or WT 1-3 duplexes was more effective than with WT 17-18 (Fig. 8). In addition, the CTC duplexes failed to compete (Fig. 8). Recombinant Sp1 formed a complex with the labeled WT 17-18 fragment, and this complex could be competed with a 240-fold excess of cold probe (Fig. 8). The slower migrating complex seen with Sp1 and WT 1-3 was not visualized in even the overexposed autoradiogram of the WT 17-18 probe (Fig. 8). Overall, these data were interpreted to suggest that the WT 1-3 (GC box 1) duplexes were capable of binding to Sp1 as efficiently as a consensus Sp1 duplexes and significantly better than the WT 17-18 (GC box 2) duplex.


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 8.   Recombinant Sp1 specifically binds WT 1-3 and WT 17-18 primers. WT 1-3 primer was radiolabeled and incubated with recombinant Sp1 (0.5 FPU/lane). Various multiples of excess of cold WT 1-3 (lanes 4-7) or WT 17-18 (lanes 8-11) were used in competition experiments. In addition, 90-fold excess of Sp1 (lane 2) and CTC (lane 3) oligonucleotides were also used. Similarly, labeled WT 17-18 primer complexed with recombinant Sp1 and could be competed off with as much as 480-fold excess of cold oligonucleotide (lanes 13-17). Filled arrowheads indicate location of DNA-protein complex. A multimerized form of Sp1 is shown with an open arrowhead.

Sp1, Sp2, and Sp3 bind to GC boxes 1 and 2. To determine whether other members of the Sp1 could account for the DNA-protein complex, supershift assays were performed. A representative gel of GC box 1 demonstrates that the lower portion of the slower migrating complex is shifted by the Sp1 antiserum (Fig. 9). Similarly, Sp2 antiserum shifted a complex that originated in a location that was similar to Sp1 (Fig. 9). In contrast, Sp3 antiserum shifted the entire faster migrating complex and a portion of the slower complex when added with the Sp1 antiserum (Fig. 9). Finally, the addition of all three antisera resulted in residual complex formation that is very similar to what was seen with the addition of both the Sp1 and Sp3 antisera (Fig. 9). These supershifted complexes were specific since the same quantity of preimmune rabbit serum failed to produce a similar supershifted complex (Fig. 9).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 9.   Supershift assay with the WT 1-3 primers with antibodies towards Sp family of proteins. Addition of 200 ng of antisera to either Sp1 (lane 2), Sp2 (lane 3), or Sp3 (lane 4) was assessed for its ability to supershift 2 DNA-protein complexes (arrowheads) formed with Caco-2 nuclear extracts. Similarly, combinations of either 2 (lanes 4-7) or 3 (lane 8) antibodies were also tested. Nonreactive serum (NR) (200 ng) was also tested (lane 9).

GC box 1 is flanked downstream by nucleotides critical for binding recombinant Sp1. To determine which nucleotides of the WT 1-3 oligonucleotide are necessary for binding Sp1, band-shift assays were performed with a 500-fold excess of a series of cold oligonucleotide duplexes containing specific mutations (Fig. 10A). Each competing oligonucleotide contained a three contiguous base pair mutation, the exact location of which is displayed in Fig. 10A. Figure 10B shows a band-shift study with labeled WT 1-3 oligonucleotide and 7 µg of Caco-2 nuclear extracts. Two complexes were identified that could be competed with 500-fold excess of the WT 1-3 primer (Fig. 10B). Primers that contained mutations in regions a, b, l, and m were capable of binding the protein(s) that form both complexes (Fig. 10B). Oligonucleotides that contained mutations in regions c-k failed to compete for binding (Fig. 10B), suggesting that the nucleotides mutated in the c-k primers are essential for binding to the protein(s) that account for the two complexes (Fig. 10A). Moreover, it appears that mutant primers g-k were able to slightly compete for binding since the intensity of both complexes was less compared with complexes competed with primers c-f (Fig. 10B).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 10.   Band-shift assay defines nucleotides in the WT 1-3 region that binds Caco-2 nuclear extracts. A: competing primers were used in 500-fold excess, and sequence of sense strand is displayed. Location of 3-bp mutation is displayed in bold, italicized, lowercase letters, and name of each primer is displayed just to left of primer. Nucleotides that are essential for binding nuclear protein are depicted within larger box in WT primer. Location of GCCCCTCCCC sequence is outlined. All primers were annealed to an antisense counterpart (not shown). B: double-stranded WT 1-3 primers were labeled with 32P and incubated with Caco-2 nuclear extracts in presence or absence of a series of cold primers (500-fold excess) that contained mutations. Cold primers used for each competition reaction are indicated above autoradiogram. C: recombinant Sp1 (0.5 FPU/lane) was incubated with WT 1-3 primers in presence or absence of 500-fold excess of cold primer. A multimerized form of Sp1 is shown with an open arrowhead. All primers were annealed to an antisense counterpart (sequence not shown). DNA-protein complexes are shown with closed arrowheads.

We investigated further the nature of the DNA-protein complexes by performing gel-shift assay with recombinant Sp1 (Fig. 10C). In this experiment, a single prominent complex was formed that resembled the slower migrating complex identified with the crude nuclear extracts (Fig. 10C). However, as in Fig. 8, a fainter and more slowly migrating complex was also seen. The addition of 500-fold excess of cold mutant primers a, b, l, and m was capable of entirely competing for recombinant Sp1 (Fig. 10C). Competition with the other primers (c-k) failed to entirely compete for the Sp1 complex, as shown previously in Fig. 10B. Finally, primers (g-k) that contained mutations outside of the critical GCCCCTCCCC region (Fig. 10A), were capable of only partially competing for the formation of the complex (Fig. 10C). Together, these results were interpreted to suggest that Sp1 and other unidentified proteins are capable of forming specific complexes with the GC box and the downstream DNA element (ATTCGCAGGACAGCTC) located between nucleotides -223 and -208 of the SGLT1 promoter.

Binding of Sp1 to the WT 17-18 primer is limited to GC box 2. Similar studies were performed with GC box 2 (the WT 17-18 oligonucleotide) and crude Caco-2 extracts. Figure 11B demonstrates that primers containing mutations in regions a-d and h could compete for binding of the nuclear proteins that are responsible for complex formation. Furthermore, primers with mutations in the e-g region (Fig. 11B) failed to compete, suggesting that nucleotides -51 to -59 (boxed nucleotides in Fig. 11A) are critical for the formation of the DNA-protein complex. The WT 1-3 primer could compete for binding of the complex formed with the WT 17-18 primer (Fig. 11B). Additional evidence suggesting that the complex is related to binding of Sp1 is provided by the ability of consensus Sp1 primer to compete for the two complexes (Fig. 11B). Similarly, the CTC oligonucleotide was able to partially compete for binding (Fig. 11B).


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 11.   Band-shift assay defines nucleotides in WT 17-18 region that bind to Caco-2 nuclear extracts. A: location of 3-bp mutation is displayed in bold, italicized, lowercase letters, and name of each primer is displayed to left. Nucleotides that are essential for binding nuclear protein are depicted within box in WT primer. CT-M primer contained a mutation that disrupted entire TCCCCTCCCC region, whereas Sp1 primer corresponds to a consensus primer that is commercially available (see EXPERIMENTAL PROCEDURES). CTC primer was identical to a primer used to define a similar element in upstream region of trefoil gene (28). B: radioactive double-stranded WT 17-18 primers were incubated with Caco-2 nuclear extracts in presence or absence of a series of cold primers that contained mutations within WT 17-18 primer. Sense strand of all competing primers is displayed below autoradiogram and were used in 500-fold excess. All primers were annealed to an overlapping antisense counterpart (sequence not shown). DNA-protein complexes are shown with closed arrowheads.

Proteins of the Sp1 multigene family and HNF-1 synergistically activate transcriptional activity of SGLT1. To determine whether the identified HNF-1 and GC boxes influence the activity of a heterologous promoter, we subcloned these elements just upstream of the SV40 promoter in the reporter vector pGL3 Promoter. All constructs contain a single copy of the identified element oriented in the 5'-to-3' direction. Because of the close apposition of the downstream GC box 2 (-63 to -55) to the HNF-1 element (-51 to -37), we also tested whether or not the two elements altered promoter activity in a synergistic manner. Compared with the enhancerless SV40 promoter construct, the addition of the GC box 1 (WT 1-3) failed to alter promoter activity (Fig. 12). Similarly, neither the HNF-1 site nor GC box 2 (WT 17-18) influenced luciferase production above what was seen with the enhancerless SV40 promoter vector. However, the addition of both the GC box 2 and the HNF-1 element enhanced promoter activity by 60% compared with control, suggesting that proteins binding to both of these sites synergistically influenced transcriptional activity in the context of the heterologous SV40 promoter.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 12.   Functional analysis of Sp1 and HNF-1 sites. Oligonucleotides containing upstream Sp1 site and downstream Sp1 element with adjacent HNF-1 site were designed and subcloned 5' to SV40 promoter. Two additional constructs were designed that contained mutations in either downstream Sp1 or HNF-1 sites. All constructs contained a single copy of identified oligonucleotide and oriented in 5' to 3' direction. Constructs were cotransfected with beta -galactosidase vector, and, 48 h later, beta -galactosidase and luciferase activity was measured. Data are displayed as percentage over empty SV40 vector.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we analyzed the basal pattern of expression of the promoter region of the human SGLT1 gene in the human intestinal cell line Caco-2. Deletion analysis of various lengths (-5295/+22 to -27/+22) of the promoter inserted upstream of the luciferase reporter indicated that nucleotides -235/+22 represent the gene's minimal promoter (Fig. 2). Within this region of the promoter, several DNA-protein complexes were identified by in vitro footprinting (Fig. 3), and mutagenesis identified three distinct sites that were responsible for enhancing the promoter activity of SGLT1 (Fig. 4).

We determined that an HNF-1 element and two GC boxes control SGLT1 basal expression in the Caco-2 cell. Two active cis-elements were found that bind members of the Sp1 family of proteins within the minimal promoter of SGLT1, and scanning mutagenesis revealed that both elements function to enhance the gene's basal expression (Fig. 4). The components of the complexes were defined by supershift analysis and revealed that portions of the two complexes are formed by binding of Sp1, Sp2, and Sp3 or a related protein(s) (Fig. 9). More specifically, the fastest-migrating DNA-protein complex was completely shifted by Sp3 antisera, whereas the slower-migrating complex appears to be at a minimum a closely migrating triplet, composed of Sp1, Sp2, Sp3, and another undefined complex.

Sp1, Sp3, and Sp4 have highly conserved zinc finger DNA binding domains and recognize the consensus GC box (5'-KRGGMGKRRY) with similar specificity and affinities, whereas Sp2 binds with much lower affinity (9). Moreover, whereas Sp1 and Sp4 have only been implicated as transcriptional activators, Sp3 usually functions as a transcriptional repressor and on occasion as an activator (1, 8, 10, 11, 13). Although Sp1 is ubiquitously expressed in all cell types examined, its level of expression varies by as much as 100-fold, and this variability has been implicated in specifying tissue and developmental-specific regulation of several genes (15, 37). Similarly, other members of the zinc finger Sp1 multigene family, Sp2 and Sp3, are ubiquitously expressed, whereas Sp4 expression is limited to the brain (9). However, an exhaustive analysis of the tissue distribution, particularly in the intestine, has not been performed for any member of the growing family of Sp1-like proteins (37). Because of the disparate levels of expression, affinity, and function of the Sp1 multigene family members, the overall impact that they may have on SGLT1 expression may be dramatic and is currently under investigation.

Gel-shift assays of GC box 1 revealed that nucleotides immediately downstream of the box (5'-ATTCGCAGGACAGCTC) were critical for complex formation with both crude and recombinant Sp1 protein (Figs. 10 and 13). Interestingly, although GC box 1 is conserved in both rat and sheep promoters, this adjacent sequence is not conserved and does not resemble a GC box (Fig. 13). Most good Sp1 binding sites are 10 nucleotides in length and do not differ from the consensus sequence at more than one position. Furthermore, Sp1 is only able to bind simultaneously to adjacent Sp1 sites if the central portions of the elements are more than 10 nucleotides apart (2). Since Sp1 is clearly capable of binding to the GC box 1, we would expect that if two Sp1 sites are occupied simultaneously, only the furthest downstream portion of the sequence would be able to bind Sp1. In fact, we failed to identify evidence that two Sp1 monomers could bind simultaneously to the GC box 1 and the adjacent downstream sequence. The faint and slowly migrating complex seen with recombinant Sp1 (Figs. 8 and 10) probably represents the multimerized form of Sp1, a process that can occur at high protein concentrations (2, 27). Therefore, it would be rather surprising if this downstream sequence could bind Sp1 independently of GC box 1. What remains unclear is how Sp1 and related proteins are capable of interacting with the adjacent nucleotides, since they do not resemble a GC box (Fig. 13). It is conceivable that the specificity of binding, including the process of multimerization, may be governed by the nucleotides that flank GC box 1. 


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 13.   GC boxes and Sp1 binding sites of WT 1-3 and WT 17-18 probe and consensus. A: Sp1 consensus site is shown in 5' to 3' orientation. B: WT 1-3 site is shown, including GC box 1 (solid line rectangle) and nucleotide-binding sites (dashed rectangle) as defined by EMSA. Potential Sp1-binding sites are shown with arrow representing strand of protein binding (i.e., leftward arrowhead 3' to 5' orientation). Small filled squares represent location of binding site that differs from Sp1 consensus. C: WT 17-18 site is also shown, including GC box 2, which was identified by EMSA.

Can the Sp1 family of proteins that bind to the two GC boxes interact with one another to synergistically activate expression of the SGLT1 gene? In many genes, GC boxes frequently occur as multiple repeat sequences (2). The repeat Sp1 sites may be either adjacent to one another or widely separated and at either distance are capable of inducing synergistic transactivation (2). Sites that are at close proximity may undergo protein-protein interactions that influence cooperative binding, whereas distal GC boxes may form multimeric complexes that enhance DNA binding and bring elements closer to the core transcriptional machinery (2). This form of synergistic activation between distal and proximal GC boxes may result from self-association of Sp1 and enhanced activity of the transcriptional complex.

Scanning mutagenesis identified that the putative HNF-1 element was also active in inducing SGLT1 basal expression. HNF-1 induces the expression of several intestinal genes, including sucrase-isomaltase, aminopeptidase, apo B, lactase, alpha -fetoprotein, alpha 1-antitrypsin, and aminopeptidase N (26, 40). HNF-1alpha is expressed in the small intestine, kidney, stomach, and liver, whereas HNF-1beta is produced in the ovary, lung, and small intestine; expression of both proteins is limited to villus epithelial cells (23, 38). The relative concentrations of HNF-1alpha and -beta differ markedly from tissue to tissue and may be developmentally regulated (44).

Rhoads et al. (33) have implicated HNF-1 in altered SGLT1 expression during the normal day and night cycles of rodents. Nuclear run-on experiments in rat intestinal epithelial cells showed that this regulation occurs at the level of transcription. Moreover, band-shift assay with nuclear extracts isolated from rat intestine identified a HNF-1 protein-DNA complex that migrated as a smear in the evening and as a faster complex in the morning. Antiserum to the HNF-1alpha isoform supershifted all complexes, implicating HNF-1alpha at all time intervals. However, antiserum for the beta  isoform abolished the migration of primarily the evening complex, indicating that HNF-1beta was a component of the evening complex. The authors suggested that this effect could be explained if the epitope recognized by the antibody is part of the HNF-1 DNA binding site. However, previous reports showed that the identical beta -antiserum did not disrupt complex formation but rather supershifted HNF-1beta when tested by band-shift technique (24). Our data showed that the HNF-1beta antiserum also abolished the slower migrating complex (Fig. 5). However, other data from our laboratory suggested that this effect was nonspecific, as other unrelated DNA-protein complexes were also disrupted by this antiserum (data not shown). Thus these data underscore the difficulty of assessing the contribution of the beta -isoform by supershift assay using currently available antisera.

The critical role of HNF-1 in controlling the regulation of genes in vivo was clearly shown in HNF-1 knockout mice. These mice developed profound multiorgan effects that resulted in a dramatic decline in survival after weaning (30, 31). They also experience failure to thrive, dramatic hepatic enlargement, severe phenylketonuria, and Fanconi syndrome, including severe glucosuria. The HNF-1 knockout mice had reduced phlorizin-binding to renal brush-border membranes, suggesting a decline in the yet-to-be-identified renal high-affinity/low-capacity cotransporter (SGLT2) (46). Interestingly, the authors did not describe diarrheal symptoms in these mice. If HNF-1 is critical in controlling SGLT1 expression, one would have expected evidence of glucose/galactose malabsorption (and consequent diarrhea) on a lactose-based diet (breast milk) (21). Similarly, the HNF-1beta knockout mice have been shown to develop a form of Laron dwarfism and non-insulin-dependent diabetes (5). In humans, heterozygous germline mutations (autosomal dominant) of either HNF-1alpha or -beta result in a poorly defined form of diabetes whose onset begins in late adolescence (MODY3) (47). Diarrhea and glucose malabsorption have not been reported in patients with MODY3.

Functional analysis suggested that proteins that bind to GC box 2 and the HNF-1 element synergistically enhanced SGLT1 promoter activity (Fig. 12). Numerous transcription factors have been shown to interact with Sp1, including GATA1, gut-enriched kruppel-like factor, AP1, NF-kappa B, GATA, and HNF-4 (35, 48). Although Sp1 enhances HNF-4-induced transcription of the apoCII promoter, the nature of the synergy between these factors was not actually defined (39). Analysis of other transcription factors suggests that the Sp1 COOH-terminal domain is involved in both synergistic activation and protein-protein interaction (39). HNF-1, on the other hand, has been shown to interact only with C/EBPalpha and to synergistically activate expression of the human albumin promoter (25). A serine-threonine- and proline-glutamine-rich region of HNF-1 is critical for its interactions with C/EBPalpha and its functional synergy at the albumin promoter. Although transcriptional synergism between Sp1 and HNF-1 has never been reported, this type of interaction may explain how a ubiquitous transcription factor like Sp1 may direct intestinal-specific expression. Interestingly, both HNF-1 and Sp1/Sp3 have been implicated in mediating glucose activation of various promoters (3, 4, 34).

Overall, this study represents the first detailed analysis of the SGLT1 promoter and the critical role that HNF-1 and Sp1 have in controlling basal transcription. In the analysis of the promoter, we have identified several unique features that deserve further attention. Although Sp1, Sp2, and Sp3 influence the basal expression of the gene via two separate GC boxes, the precise role that these and other members of the Sp1 multigene family have in altering expression of the gene has not been determined. Sp1 was shown to interact with GC box 1, but the nature of how the 16-nucleotide element immediately downstream of the box confers specific binding to Sp1 remains unexplored. Finally, the mechanism by which Sp1 and HNF-1 synergistically influence SGLT1 gene expression should be further analyzed since it may be a general model for understanding the mechanism of intestinal-specific gene expression.


    ACKNOWLEDGEMENTS

This research was supported by grants from the National Institutes of Health (HD-34706 and DK-44582), the Robert Wood Johnson Foundation Faculty Training program, and the American Gastroenterology Industry Training Award.


    FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: M. G. Martín, Dept. of Pediatrics, Div. of Gastroenterology and Nutrition, UCLA School of Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095-1751 (E-mail: mmartin{at}mednet.ucla.edu).

Received 2 November 1999; accepted in final form 9 December 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1.   Bigger, CB, Melnikova IN, and Gardner PD. Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor B4 subunit gene. J Biol Chem 272: 25976-25982, 1997[Abstract/Free Full Text].

2.   Courey, AJ, and Tjian R. Mechanisms of Transcriptional Control as Revealed by Studies of Human Transcription Factor Sp1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1992, p. 743-769. (Transcriptional Regulation Monogr, 22)

3.   Cuif, M-H, Porteu A, Kahn A, and Vaulont S. Exploration of a liver-specific, glucose/insulin-responsive promoter in transgenic mice. J Biol Chem 268: 13769-13772, 1993[Abstract/Free Full Text].

4.   Daniel, S, and Kim K. Sp1 mediates glucose activation of the acetyl-coA carboxylase promoter. J Biol Chem 271: 1385-1392, 1996[Abstract/Free Full Text].

5.   Dukes, ID, Sreenan S, Roe MW, Levisetti M, Zhou YP, Ostrega D, Bell GI, Pontoglio M, Yaniv M, Philipson L, and Polonsky KS. Defective pancreatic beta -cell glycolytic signaling in hepatocyte nuclear factor-1alpha -deficient mice. J Biol Chem 273: 24457-24464, 1998[Abstract/Free Full Text].

6.   Ernst, P, and Smale ST. Combinatorial regulation of transcription I: General aspects of transcriptional control. Immunity 2: 311-319, 1995[ISI][Medline].

7.   Ferraris, RP, and Diamond J. Regulation of intestinal sugar transport. Physiol Rev 77: 257-302, 1997[Abstract/Free Full Text].

8.   Hagen, G, Dennig J, Preib A, Beato M, and Suske G. Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol Chem 270: 24989-24994, 1995[Abstract/Free Full Text].

9.   Hagen, G, Muller S, Beato M, and Suske G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res 20: 5519-5525, 1992[Abstract].

10.   Hagen, G, Muller S, Beato M, and Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 13: 3843-3851, 1994[Abstract].

11.   Hata, Y, Duh E, Zhang K, Robinson GS, and Aiello LP. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 273: 19294-19303, 1998[Abstract/Free Full Text].

12.   Hediger, MA, and Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74: 993-1026, 1994[Free Full Text].

13.   Kwon, HS, Kim MS, Edenberg HJ, and Hur MW. Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter. J Biol Chem 274: 20-28, 1999[Abstract/Free Full Text].

14.   Lam, JT, Martín MG, Turk E, Hirayama BA, Bosshard NU, Steinmann B, and Wright EM. Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Biochim Biophys Acta 1453: 297-303, 1999[ISI][Medline].

15.   Lania, L, Majello B, and De Luca P. Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol 29: 1313-1323, 1997[ISI][Medline].

16.   Lescale-Matys, L, Dyer J, Scott D, Freeman TC, Wright EM, and Shirazi-Beechey SP. Regulation of the ovine intestinal Na+/glucose co-transporter (SGLT1) is dissociated from mRNA abundance. Biochem J 291: 435-440, 1993[ISI][Medline].

17.   Li, TWH, Wang JF, Lam JT, Gutierrez EM, Solorzano-Vargus RS, Tsai HV, and Martín MG. Transcriptional control of the murine polymeric IgA receptor promoter by glucocorticoids. Am J Physiol Gastrointest Liver Physiol 276: G1425-G1434, 1999[Abstract/Free Full Text].

18.   Mahraoui, L, Rodolosse A, Barbat A, Dussaulx E, Zweibaum A, Rousset M, and Brot-Laroche E. Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell growth and glucose consumption. Biochem J 298: 629-633, 1994[ISI][Medline].

19.   Markowitz, AJ, Wu GD, Birkenmeier EH, and Traber PG. The human sucrase-isomaltase gene directs complex patterns of gene expression in transgenic mice. Am J Physiol Gastrointest Liver Physiol 265: G526-G539, 1993[Abstract/Free Full Text].

20.  Martín MG, Turk E, Kerner C, and Wright EM. Compound missense mutations in sodium/D-glucose cotransporter (SGLT1) results in trafficking defects. Gastroenterology 112: 1206-1212.

21.   Martín, MG, Turk E, Lostao MP, Kerner C, and Wright EM. Defects in Na+ glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12: 216-220, 1996[ISI][Medline].

22.   Martín, MG, Wang JF, Li TWH, Lam JT, Gutierrez EM, Solorzano-Vargas RS, and Tsai HV. Characterization of the 5'-flanking region of the murine polymeric IgA receptor gene. Am J Physiol Gastrointest Liver Physiol 275: G778-G788, 1998[Abstract/Free Full Text].

23.   Mendel, DB, and Crabtree GR. HNF-1, a member of a novel class of dimerizing homeodomain proteins. J Biol Chem 266: 677-680, 1991[Free Full Text].

24.   Mendel, DB, Hansen LP, Graves MK, Conley PB, and Crabtree GR. HNF-1alpha and HNF-1beta (vHNF-1) share dimerization and homeo domains, but not activation domains, and form hererodimers in vitro. Genes Dev 5: 1042-1056, 1991[Abstract].

25.   Merika, M, and Orkin SH. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol Cell Biol 15: 2437-2447, 1995[Abstract].

26.   Mitchelmore, C, Troelsen JT, Sjöström H, and Norén O. The HOXC11 homeodomain protein interacts with the lactase-phlorizin hydrolase promoter and stimulates HNF1 alpha -dependent transcription. J Biol Chem 273: 13297-13306, 1998[Abstract/Free Full Text].

27.   Nardelli, J, Gibson TJ, Vesque C, and Charnay P. Base sequence discrimination by zinc-finger DNA-binding domains. Nature 349: 175-178, 1999.

28.   Ogata, H, Inoue N, and Podolsky DK. Identification of a goblet cell-specific enhancer element in the rat intestinal trefoil factor gene promoter bound by a goblet cell nuclear protein. J Biol Chem 273: 3060-3067, 1998[Abstract/Free Full Text].

29.   Peng, H, and Lever JE. Post-transcriptional regulation of Na+/glucose cotransporter (SGTL1) gene expression in LLC-PK1 cells---increased message stability after cyclic AMP elevation or differentiation inducer treatment. J Biol Chem 270: 20536-20542, 1995[Abstract/Free Full Text].

30.   Pontoglio, M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, and Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575-585, 1996[ISI][Medline].

31.   Pontoglio, M, Faust DM, Doyen A, Yaniv M, and Weiss MC. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. Mol Cell Biol 17: 4948-4956, 1997[Abstract].

32.   Quandt, K, Frech K, Karas H, Wingender E, and Werner T. MatInd and MatInspector---new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23: 4878-4884, 1995[Abstract].

33.   Rhoads, DB, Rosenbaum Unsal H, Isselbacher KJ, and Levitsky LL. Circadian periodicity of intestinal Na+/glucose cotransporter 1 mRNA levels is transcriptionally regulated. J Biol Chem 273: 9510-9516, 1998[Abstract/Free Full Text].

34.   Rodolosse, A, Carriere V, Rousset M, and Lacasa M. Two HNF-1 binding sites govern the glucose repression of the human sucrase-isomaltase promoter. Biochem J 336: 115-123, 1998[ISI][Medline].

35.   Rosmarin, AG, Menglin L, Caprios DG, Shang J, and Simkevich CP. Sp1 cooperates with the ets transcription factor, GABP, to activate the CD18 (B2 leukocyte integrin) promoter. J Biol Chem 273: 13097-13103, 1998[Abstract/Free Full Text].

36.   Rottman, JN, and Gordon JI. Comparison of the patterns of expression of rat intestinal fatty acid binding protein/human growth hormone fusion genes in cultured intestinal epithelial cell lines and in the gut epithelium of transgenic mice. J Biol Chem 268: 11994-12002, 1993[Abstract/Free Full Text].

37.   Saffer, JD, Jackson SP, and Annarella MB. Developmental expression of Sp1 in the mouse. Mol Cell Biol 11: 2189-2199, 1991[ISI][Medline].

38.   Serfas, MS, and Tyner AL. HNF-1alpha and HNF-1beta expression in mouse intestinal crypts. Am J Physiol Gastrointest Liver Physiol 265: G506-G513, 1993[Abstract/Free Full Text].

39.   Talianidis, I, Tambakaki A, Toursounova J, and Zannis VI. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry 34: 10298-10309, 1995[ISI][Medline].

40.   Traber, PG, and Silberg DG. Intestine-specific gene transcription. Annu Rev Physiol 58: 275-297, 1996[ISI][Medline].

41.   Turk, E, Klisak I, Bacallao R, Sparkes RS, and Wright EM. Assignment of the human Na+/glucose cotransporter gene SGLT1 to chromosome 22q13.1. Genomics 17: 752-754, 1993[ISI][Medline].

42.   Turk, E, Martín MG, and Wright EM. Structure of the human Na+/glucose cotransporter gene SGLT1. J Biol Chem 269: 15204-15209, 1994[Abstract/Free Full Text].

43.   Turk, E, Zabel B, Mundlos S, Dyer J, and Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 350: 354-356, 1991[ISI][Medline].

44.   Von Strandmann, EP, Nastos A, Holewa B, Senkel S, Weber H, and Ryffel GU. Patterning the expression of a tissue-specific transcription factor in embryogenesis: HNF1alpha gene activation during Xenopus development. Mech Dev 64: 7-17, 1997[ISI][Medline].

45.   Wood, IS, Allison GG, and Shirazi-Beechey SP. Isolation and characterization of a genomic region upstream from the ovine Na+/D-glucose cotransporter (SGLT1) cDNA. Biochem Biophys Res Commun 257: 533-537, 1999[ISI][Medline].

46.   Wright, EM, Hirayama BA, Loo DDF, Turk E, and Hager K. Intestinal sugar transport. In: Physiology of the Gastrointestinal Tract, edited by Johnson LR.. New York: Raven, 1994, p. 1751-1772.

47.   Yamagata, K, Oda N, Kaisaki P, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Borlraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, and Bell GI. Mutations in the hepatoxyte nuclear factor-I alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384: 455-458, 1996[ISI][Medline].

48.   Zhang, WQ, Shields JM, Sogawa K, Fujii-Kuriyama Y, and Yang VW. The gut-enriched Kruppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion. J Biol Chem 273: 17917-17925, 1998[Abstract/Free Full Text].


Am J Physiol Gastrointest Liver Physiol 278(4):G591-G603
0193-1857/00 $5.00 Copyright © 2000 the American Physiological Society